Display options
Cite
Wlazeł RN, Migała M, Zielińska M, et al. Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention. Arch Med Sci. 2016;15(1):72-77doi: 10.5114/aoms.2016.63596.
Wlazeł, R. N., Migała, M., Zielińska, M., Pawlicki, L., Rośniak-Bąk, K., & Szadkowska, I. (2019). Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention. Archives of medical science : AMS, 15(1), 72-77. https://doi.org/10.5114/aoms.2016.63596
Wlazeł, Rafał N, et al. "Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention." Archives of medical science : AMS vol. 15,1 (2019): 72-77. doi: https://doi.org/10.5114/aoms.2016.63596
Wlazeł RN, Migała M, Zielińska M, Pawlicki L, Rośniak-Bąk K, Szadkowska I. Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention. Arch Med Sci. 2019 Jan;15(1):72-77. doi: 10.5114/aoms.2016.63596. Epub 2016 Nov 15. PMID: 30697255; PMCID: PMC6348361.
Copy Download .nbib Format: NLM
Share it on

Arch Med Sci. 2019 Jan;15(1):72-77. doi: 10.5114/aoms.2016.63596. Epub 2016 Nov 15.

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention.

Archives of medical science : AMS

Rafał N Wlazeł, Marta Migała, Marzenna Zielińska, Lucjan Pawlicki, Kinga Rośniak-Bąk, Iwona Szadkowska

Affiliations

  1. Department of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, Lodz, Poland.
  2. Department of Intensive Cardiac Therapy, Medical University of Lodz, Lodz, Poland.
  3. Department of Internal Diseases and Cardiological Rehabilitation, Medical University of Lodz, Lodz, Poland.

PMID: 30697255 PMCID: PMC6348361 DOI: 10.5114/aoms.2016.63596

Abstract

INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) level reflects the general condition of the organism and was proved to give independent information in risk stratification of patients. The aim of this study was to assess the usefulness of suPAR in the prediction of adverse cardiac events in patients with first myocardial infarction (MI) undergoing primary percutaneous coronary intervention. Additionally, the diagnostic power of suPAR was assessed.

MATERIAL AND METHODS: One hundred and thirty-nine of 150 consecutive patients were included in the study. Serum suPAR level (ELISA, Virogates) as well as C-reactive protein (on admission and at discharge) and maximum troponin T (assessed from successive 6-hour periods of blood collection) were measured. In the 1-year follow-up study the following major adverse cardiac events were observed: myocardial infarction, revascularization, stroke and death.

RESULTS: Multi-variable analysis revealed prognostic usefulness only for suPAR and glomerular filtration rate:

CONCLUSIONS: Soluble urokinase plasminogen activator receptor level appears to be an independent useful biomarker for the prediction of major adverse cardiac events early after first myocardial infarction. The biomarker's level seems to have more prognostic than diagnostic power.

Keywords: biomarkers; cardiovascular risk prediction; prognostication after acute myocardial infarction

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Blood. 2000 Dec 15;96(13):4091-5 - PubMed
  2. Med Res Rev. 2004 Jan;24(1):13-39 - PubMed
  3. J Infect Dis. 2005 Apr 15;191(8):1331-41 - PubMed
  4. J Intern Med. 2010 Sep;268(3):296-308 - PubMed
  5. Atherosclerosis. 2011 May;216(1):237-43 - PubMed
  6. Crit Care. 2011;15(6):1020 - PubMed
  7. Int J Cardiol. 2013 Aug 10;167(3):781-5 - PubMed
  8. Int J Cardiol. 2013 Sep 10;167(6):2904-11 - PubMed
  9. Am J Cardiol. 2012 Dec 15;110(12):1756-63 - PubMed
  10. Clin Chem. 2013 Nov;59(11):1621-9 - PubMed
  11. Biomarkers. 2013 Dec;18(8):655-9 - PubMed
  12. Cardiol J. 2013;20(6):577-82 - PubMed
  13. PLoS One. 2014 Jun 09;9(6):e98923 - PubMed
  14. Atherosclerosis. 2014 Nov;237(1):60-6 - PubMed
  15. J Am Heart Assoc. 2014 Oct 23;3(5):e001118 - PubMed
  16. Arch Med Sci. 2014 Dec 22;10(6):1091-100 - PubMed
  17. Can J Cardiol. 2015 Oct;31(10):1293-302 - PubMed
  18. Arch Med Sci. 2017 Jun;13(4):771-777 - PubMed

Publication Types